Iopamiro 300 (Iopamidol)

Iopamidol contains iodine atoms that strongly absorb X‑ray photons. When injected, these atoms create radiodense zones that appear brighter on radiographs, allowing clinicians to differentiate vascular, joint or spinal structures from surrounding tissues during imaging procedures.

The dose of Iopamiro 300 is determined by the prescribing physician based on the specific imaging protocol, patient size, and the anatomical area to be examined. The prescriber selects the appropriate volume and concentration to achieve optimal contrast while minimizing exposure.

Safety of Iopamiro 300 in pregnancy and lactation has not been established. It should only be used when clearly needed and when the potential diagnostic benefit outweighs any possible risk to the fetus or infant. Consultation with obstetric specialists is recommended.

To order Iopamiro 300, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Iopamiro 300 (iopamidol) offers a low‑osmolality profile similar to other modern agents such as iohexol, providing good image quality with a reduced incidence of discomfort and adverse reactions compared with high‑osmolality agents. Choice between agents often depends on specific imaging needs, institutional protocols and patient tolerance.

Iopamiro 300 should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep the product in its original packaging until use to maintain sterility and potency.

Iopamiro 300 is administered by a qualified healthcare professional via intra‑arterial, intra‑articular or intrathecal injection, depending on the imaging study. The solution is injected directly into the target vascular, joint or spinal space under controlled conditions, often using a power injector for consistent delivery.

The most serious risks include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute renal failure, and cardiovascular events like severe hypotension or arrhythmias. Immediate medical attention is required if any of these reactions occur.

Iopamiro 300 should be avoided in patients with a known hypersensitivity to iodine or iodinated contrast media, those with severe renal impairment (eGFR <30 mL/min/1.73 m²), and individuals who have experienced prior severe reactions to contrast agents. Clinicians must assess risk before administration.